BioCentury
ARTICLE | Company News

GlaxoSmithKline, Sanofi-Synthelabo SA deal

April 19, 2004 7:00 AM UTC

GSK will pay E453 million ($547.7 million) in cash for global rights to SAN's Fraxiparine nadroparine low molecular weight heparin and Arixtra fondaparinux synthetic Factor Xa inhibitor, both injec...